2-methoxy-6-(piperidin-4-yl)pyridine hydrochloride | 1137950-63-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methoxy-6-(piperidin-4-yl)pyridine hydrochloride
• 英文别名: 2-Methoxy-6-piperidin-4-ylpyridine;hydrochloride
• CAS: 1137950-63-0
• 化学式: C₁₁H₁₆N₂O*ClH
• 分子量: 228.722
• InChiKey: XGQOKMZIBPVSRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.98
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyl 4-(6-methoxypyridin-2-yl)piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 8.0h， 以82%的产率得到2-methoxy-6-(piperidin-4-yl)pyridine hydrochloride
  参考文献：
  名称：

  WO2019243851A5

  摘要：

  公开号：

  WO2019243851A5

文献信息

• BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3406609A1

  公开（公告）日：2018-11-28

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1b or a salt thereof, wherein Q, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括符合式 1b 的化合物 或其盐，其中 Q、R3 和 R4 如本文所定义。
• Pharmaceutical compounds
  申请人：Heptares Therapeutics Limited

  公开号：US10787447B2

  公开（公告）日：2020-09-29

  This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R1, R2 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 和/或 M4 受体的激动剂，可用于治疗由毒蕈碱 M1 和 M4 受体介导的疾病。本发明还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物为式 其中 Y、R1、R2 和 R4 如本文所定义。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.
  申请人：Heptares Therapeutics Limited

  公开号：EP3102568B1

  公开（公告）日：2018-06-27
• BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR
  申请人：Heptares Therapeutics Limited

  公开号：EP3810614A1

  公开（公告）日：2021-04-28
• PHARMACEUTICAL COMPOUNDS
  申请人：Heptares Therapeutics Limited

  公开号：US20210002271A1

  公开（公告）日：2021-01-07

  This invention relates to compounds that are agonists of the muscarinic M 1 and/or M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R 1 , R 2 and R 4 are as defined herein.